These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 11923819)
1. US wary of South Korean plans for Californian biocenter. Niiler E Nat Biotechnol; 2002 Apr; 20(4):321. PubMed ID: 11923819 [No Abstract] [Full Text] [Related]
2. Winners and losers in merger mania. Niiler E Nat Biotechnol; 1999 Nov; 17(11):1058. PubMed ID: 10545903 [No Abstract] [Full Text] [Related]
5. What affects the innovation performance of small and medium-sized enterprises (SMEs) in the biotechnology industry? An empirical study on Korean biotech SMEs. Kang KN; Lee YS Biotechnol Lett; 2008 Oct; 30(10):1699-704. PubMed ID: 18506395 [TBL] [Abstract][Full Text] [Related]
6. Tough cell to investors. Venture capitalists are wary of investing in companies in which risks in the science may not be rewarded by a health revenue stream. Moran N Sci Am; 2005 Jul; 293(1):A32-4. PubMed ID: 16008299 [No Abstract] [Full Text] [Related]
7. Paring down the company: the effect of consolidation in the European biotech sector. Bassett P Nat Biotechnol; 2003 Jul; 21(7):829-30. PubMed ID: 12833105 [No Abstract] [Full Text] [Related]
8. Korean biotechs seize opportunity to list on public markets. Louët S Nat Biotechnol; 2005 Oct; 23(10):1189-90. PubMed ID: 16211042 [No Abstract] [Full Text] [Related]
9. Making the biotech IPO work. McNamee L; Ledley F Nat Biotechnol; 2013 Nov; 31(11):969-70. PubMed ID: 24213765 [No Abstract] [Full Text] [Related]
10. South Korean biotechnology--a rising industrial and scientific powerhouse. Wong J; Quach U; Thorsteinsdóttir H; Singer PA; Daar AS Nat Biotechnol; 2004 Dec; 22 Suppl():DC42-7. PubMed ID: 15583684 [No Abstract] [Full Text] [Related]